全文获取类型
收费全文 | 68807篇 |
免费 | 7740篇 |
国内免费 | 1589篇 |
专业分类
耳鼻咽喉 | 753篇 |
儿科学 | 2188篇 |
妇产科学 | 494篇 |
基础医学 | 11110篇 |
口腔科学 | 1181篇 |
临床医学 | 5956篇 |
内科学 | 14299篇 |
皮肤病学 | 1462篇 |
神经病学 | 7054篇 |
特种医学 | 895篇 |
外国民族医学 | 4篇 |
外科学 | 5173篇 |
综合类 | 7663篇 |
现状与发展 | 6篇 |
一般理论 | 1篇 |
预防医学 | 3767篇 |
眼科学 | 693篇 |
药学 | 8120篇 |
30篇 | |
中国医学 | 3392篇 |
肿瘤学 | 3895篇 |
出版年
2024年 | 193篇 |
2023年 | 1027篇 |
2022年 | 1986篇 |
2021年 | 3762篇 |
2020年 | 2678篇 |
2019年 | 2578篇 |
2018年 | 2528篇 |
2017年 | 2810篇 |
2016年 | 2852篇 |
2015年 | 3347篇 |
2014年 | 4650篇 |
2013年 | 4668篇 |
2012年 | 4460篇 |
2011年 | 4622篇 |
2010年 | 3740篇 |
2009年 | 3428篇 |
2008年 | 3553篇 |
2007年 | 2830篇 |
2006年 | 2537篇 |
2005年 | 2382篇 |
2004年 | 1971篇 |
2003年 | 1727篇 |
2002年 | 1438篇 |
2001年 | 1328篇 |
2000年 | 1054篇 |
1999年 | 1010篇 |
1998年 | 1089篇 |
1997年 | 953篇 |
1996年 | 800篇 |
1995年 | 663篇 |
1994年 | 618篇 |
1993年 | 634篇 |
1992年 | 498篇 |
1991年 | 415篇 |
1990年 | 367篇 |
1989年 | 293篇 |
1988年 | 294篇 |
1987年 | 302篇 |
1986年 | 361篇 |
1985年 | 338篇 |
1984年 | 263篇 |
1983年 | 223篇 |
1982年 | 215篇 |
1981年 | 196篇 |
1980年 | 142篇 |
1979年 | 88篇 |
1978年 | 62篇 |
1977年 | 48篇 |
1976年 | 41篇 |
1975年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
4.
5.
6.
7.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
8.
《The Journal for Nurse Practitioners》2022,18(2):245-247
Transient stress hyperglycemia in the setting of acute myocardial infarction is a frequent phenomenon. Its transient nature should not dissuade the clinician from management of elevated blood glucose in a patient after an ST-elevation myocardial infarction. This case presents an adult patient after an ST-elevation myocardial infarction with transient stress hyperglycemia and the evidence used to identify optimal pharmacologic management and secondary prevention. 相似文献
9.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献